Estrogen Via Patch Superior for Menopausal Sexual Symptoms

Share this content:
Estrogen Via Patch Superior for Menopausal Sexual Symptoms
Estrogen Via Patch Superior for Menopausal Sexual Symptoms

TUESDAY, Aug. 29, 2017 (HealthDay News) -- Supplemental estrogens may be beneficial for sexual function in menopausal women, but the form of medication delivery appears to matter, according to a study published online Aug. 28 in JAMA Internal Medicine.

Hugh Taylor, M.D., of the Yale School of Medicine in New Haven, Conn., and colleagues tracked changes in sexual function for a group of 670 women who entered menopause within the past three years. The women ranged in age from 42 to 58 and were treated with either supplemental oral estrogen, estrogen delivered via skin patch, or placebo. The study participants also completed questionnaires about their sexual function, including any issues with desire, satisfaction, and pain.

The researchers found that, overall, the women who received patch estrogen therapy experienced moderate improvements in their sexual function over four years of treatment compared to women in the placebo group. There were no significant improvements noted for the oral estrogen therapy versus placebo. Specifically, women who used the patch had less dryness and sex-related pain than the women in the placebo group. When compared with the placebo group, the proportion of women with low sexual function was also lower following patch estrogen therapy. Again, however, that benefit wasn't seen when estrogen was delivered in oral form.

According to Taylor, the study highlights that supplemental estrogen isn't a "one-size-fits-all" strategy. "The estrogen mode of delivery can be personalized to the predominant symptom in an individual," Taylor told HealthDay. So, "while topical estrogens may be best for sexual function, oral estrogens may be best for improving mood. They are not all the same."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »